We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    218079
Previous Study | Return to List | Next Study

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) (ANCHOR-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05281523
Recruitment Status : Recruiting
First Posted : March 16, 2022
Last Update Posted : January 20, 2023
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with CRSwNP.

Condition or disease Intervention/treatment Phase
Nasal Polyps Biological: Depemokimab (GSK3511294) Drug: Placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will receive either depemokimab (GSK3511294) or placebo during the study.
Masking: Double (Participant, Investigator)
Masking Description: This will be a double-blind study.
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)
Actual Study Start Date : April 18, 2022
Estimated Primary Completion Date : November 21, 2024
Estimated Study Completion Date : November 21, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Participants receiving depemokimab (GSK3511294) Biological: Depemokimab (GSK3511294)
Depemokimab (GSK3511294) will be administered using a pre-filled syringe.
Placebo Comparator: Participants receiving Placebo Drug: Placebo
Placebo will be administered as normal saline using a pre-filled syringe.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from Baseline in total endoscopic nasal polyps (NP) score at Week 52 (scores on a scale) [ Time Frame: Baseline and at Week 52 ]
    NP score is graded based on NP size and recorded as the sum of the right and left nostril scores evaluated by nasal endoscopy. The total endoscopic NP score ranges between 0 (no polyps) to 8 (large polyps); higher scores indicate worse status.

  2. Change from Baseline in mean nasal obstruction score using verbal response scale (VRS) from Weeks 49 to 52 (scores on a scale) [ Time Frame: Baseline and from Week 49 to Week 52 ]
    Participants will be asked to indicate the severity of nasal obstruction at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This will be scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms).


Secondary Outcome Measures :
  1. Change from Baseline in mean symptom score for rhinorrhea (runny nose) using VRS (scores on a scale) [ Time Frame: Baseline and from Week 49 to Week 52 ]
    Participants will be asked to indicate the severity of rhinorrhea (runny nose) at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This will be scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms).

  2. Change from Baseline in mean symptom score for loss of smell using VRS (scores on a scale) [ Time Frame: Baseline and from Week 49 to Week 52 ]
    Participants will be asked to indicate the severity of loss of smell at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This will be scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms.

  3. Change from Baseline in Lund Mackay (LMK) computed tomography (CT) score (scores on a scale) [ Time Frame: Baseline and at Week 52 ]
    The LMK CT scoring system is based on CT imaging of the sinuses with points given for degree of opacification: 0 =normal, 1 = partial opacification, 2 = total opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side (right and left). The osteomeatal complex (OC) is graded as 0 = not occluded, or 2 = occluded deriving a maximum score of 12 per side. The range for the total LMK CT score is therefore 0 (normal) to 24 (total opacification) when summed across both sides.

  4. Change from Baseline in Sino-nasal Outcome Test (SNOT)-22 total score (scores on a scale) [ Time Frame: Baseline and at Week 52 ]
    SNOT-22 is a 22-item measure of disease specific health related quality of life (HRQoL). Participants will be asked to rate the severity of their condition on each of the 22 items over the previous 2 weeks using a 6-point rating scale of 0 (not present/no problem) to 5 (Problem as bad as it can be). The total score range for the SNOT-22 is 0-110, where higher scores indicate greater disease impact

  5. Change from Baseline in Asthma Control Questionnaire (ACQ-5) score (scores on a scale) [ Time Frame: Baseline and at Week 52 ]
    The ACQ-5 is a 5-item questionnaire which enquires about the frequency and/or severity of asthma symptoms over the previous week (nocturnal awakening on waking in the morning, activity limitation, and shortness of breath, wheeze). Each question is scored from 0 (no impairment/limitation) to 6 (total impairment/ limitation). Higher score indicates more limitations. Impact on asthma control in participants with an ACQ-5 score greater than (>)0.75 at Baseline will be assessed.

  6. Change from Baseline in mean nasal obstruction score using VRS from Weeks 21 to 24 (scores on a scale) [ Time Frame: Baseline and from Week 21 to Week 24 ]
    Participants will be asked to indicate the severity of nasal obstruction at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This will be scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms) ranging from 0 (no symptoms).

  7. Change from Baseline in total endoscopic NP score at Week 26 (scores on a scale) [ Time Frame: Baseline and at Week 26 ]
    NP score is graded based on NP size and recorded as the sum of the right and left nostril scores evaluated by nasal endoscopy. The total endoscopic NP score ranges between 0 (no polyps) to 8 (large polyps); higher scores indicate worse status.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants with 18 years of age and older inclusive, at the time of signing the informed consent.
  • Endoscopic bilateral NP score of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity) assessed by the investigator.
  • Participants who have had at least one of the following at Visit 1: Previous nasal surgery for the removal of NP; Have used at least three consecutive days of systemic corticosteroids in the previous 2 years for the treatment of NP; Medically unsuitable or intolerant to systemic corticosteroid.
  • Participants (except for those in Japan) must be on daily treatment with intranasal corticosteroids (INCS) (including intranasal liquid steroid wash/douching) for at least 8 weeks prior to screening.
  • Participants presenting with severe NP symptoms defined as symptoms of nasal congestion/blockade/obstruction with moderate or severe severity and loss of smell or rhinorrhea (runny nose) based on clinical assessment by the investigator.
  • Presence of symptoms of chronic rhinosinusitis as described by at least 2 different symptoms for at least 12 weeks prior to Visit 1, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip), plus facial pain/pressure and/or reduction or loss of smell.
  • Male or eligible female participants

Exclusion Criteria:

  • As a result of medical interview, physical examination, or screening investigation the physician responsible considers the participant unfit for the study.
  • Cystic fibrosis.
  • Antrochoanal polyps.
  • Nasal cavity tumor (malignant or benign)
  • Fungal rhinosinusitis
  • Severe nasal septal deviation occluding one nostril preventing full assessment of nasal polyps in both nostrils.
  • Participants who had a sino-nasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of nasal polyp score.
  • Acute sinusitis or upper respiratory tract infection (URTI) at screening or in 2 weeks prior to screening.
  • Ongoing rhinitis medicamentosa (rebound or chemical induced rhinitis).
  • Participants who have had an asthma exacerbation requiring admission to hospital within 4 weeks of Screening.
  • Participants who have undergone any intranasal and/or sinus surgery (for example polypectomy, balloon dilatation or nasal stent insertion) within 6 months prior to Visit 1; nasal biopsy prior to Visit 1 for diagnostic purposes only is excepted.
  • Participants where NP surgery is contraindicated in the opinion of the Investigator.
  • Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) eosinophilic granulomatosis with polyangiitis (EGPA) (formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis.
  • Participants with a known, pre-existing parasitic infestation within 6 months prior to Visit 1.
  • A known immunodeficiency (e.g. human immunodeficiency virus (HIV), other than that explained by the use of corticosteroids (CSs) taken as therapy for asthma.
  • A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.
  • Liver Disease: Alanine aminotransferase (ALT) >2 times upper limit normal (ULN); Total bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin less than [<]35 percent [%]); Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Participants who have known, pre-existing, clinically significant cardiac, endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment.
  • Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrollment.
  • Hypersensitivity: Participants with allergy/intolerance to the excipients of depemokimab (GSK3511294) in a monoclonal antibody, or biologic.
  • Participants that, according to the investigator's medical judgment, are likely to have active Coronavirus disease-2019 (COVID-19) infection must be excluded. Participants with known COVID-19 positive contacts within the past 14 days must be excluded for at least 14 days following the exposure during which the participant should remain symptom-free. Reported smell/ taste complications from COVID-19 must be used as exclusion.
  • Participants that have been exposed to ionising radiation in excess of 10 millisievert (mSv) above background over the previous 3-year period as a result of occupational exposure or previous participation in research studies.
  • Previously participated in any study with mepolizumab, reslizumab, or benralizumab and received study intervention (including placebo) within 12 months prior to Visit 1.
  • Women who are pregnant or lactating or are planning on becoming pregnant during the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05281523


Contacts
Layout table for location contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 89904466 GSKClinicalSupportHD@gsk.com

Locations
Show Show 85 study locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT05281523    
Other Study ID Numbers: 218079
First Posted: March 16, 2022    Key Record Dates
Last Update Posted: January 20, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
URL: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GlaxoSmithKline:
Depemokimab
GSK3511294
Chronic rhinosinusitis
Verbal response scale
 Asthma Control Questionnaire
Lund Mackay computed tomography
Nasal polyps score
Nasal endoscopy
Additional relevant MeSH terms:
Layout table for MeSH terms
Nasal Polyps
Polyps
Pathological Conditions, Anatomical
 Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases